Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.
तुलना करने के लिए मीट्रिक्स | DRUG | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधDRUGपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −126.3x | −5.8x | −0.7x | |
PEG अनुपात | −1.92 | −0.05 | 0.00 | |
क़ीमत/बुक | 74.1x | 2.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 14.6x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | 15.2% | 304.9% | 45.9% | |
उचित मूल्य अपसाइड | अनलॉक करें | 19.6% | 7.6% | अनलॉक करें |